Website_AkihideYoshimi

(Last update Feb17 2016)



Curriculum Vitae

 

Name: Akihide Yoshimi

 

Nationality: Japanese

Email Address: yoshimia[at]mskcc.org

Work address: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 417 East 68th Street New Yorl, NY 10065, USA


Date of birth: 15.3.1978

Education

1. April 1997 - March 2003  MD. Faculty of Medicine, The University of Tokyo, Japan

2. April 2007 - March 2011  PhD thesis at the Graduate School of Medicine,

The University of Tokyo, Japan

 

Work history

1. Jun 2003 - May 2004  Residency at the University of Tokyo Hospital (Internal Medicine)

2. Jun 2004 - May 2005  Residency at the Kanto Medical Center NTT (Internal Medicine)

Jun 2005 - May 2006  Senior residency at the Kanto Medical Center NTT

3. Jun 2006 - Dec 2007  Senior residency at the Department of Hematology and Oncology, The University of Tokyo Hospital

4. Apr 2009 - Mar 2011  Research Fellowship for Young Scientist of JSPS
(Japan Society for the Promotion of Science)

5. Apr 2011 - Nov 2013  Assistant Professor at the Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital
   

6. Dec 2013 -May 2015  Project Assistant Professor at the Department of Hematology and Oncology,
Graduate School of Medicine, The University of Tokyo

7. July 2015 -June 2018 Visiting Investigator,  Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center

8. July 2018 - present Senior Research Scientist, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center

  

Scholarship/Award/Grant

1. Grants-in-Aid for Scientific Research of the Japan Society for the Promotion of Science (JSPS) (April 2009 - March2011)

2. Sachi Nakashima Award / Keystone Symposia Scholarship (2010)

3. Japan Leukemia Research Fund (2010)

4. Encouraging Prize from Japanese Society of Hematology (2010)

5. The 8th Young Hematologist Award from Kyowa Hakko-Kirin Co., Ltd (2012)

6. Sensin Medical Research Fundation (2012

7. Grant-in-Aid for Young Scientists (B) (2012)

8. The Ichiro Kanehara Foundation for the Promotion of Medical Sciences (2012)

9. Takeda Science Foundation (2013)

10. Mitsui Sumitomo Insurance Welfare Foundation (2013)

11. Japan Leukemia Research Fund (Special Award for Young Researchers) (2013)

12. Foundation for Promotion of Cancer Research (2013)

13. Special Award for Young Researchers from Japan Leukaemia Research Fund (2013)

14. Grant-in-Aid for Young Scientists (B) (2014)

15. COI STREAM (Center of Innovation Science and Technology based Radical Innovation and Entrepreneurship Program) (2014)

16. Ikeda Scientific Award (2014)

17. Nihon Unisys Award (2014)

18. Ikeda Scientific Award from Ikeda Scientific Co., Ltd (2014)

19. Nihon Unisys Award from Nihon Unisys Ltd (2014)

20. Terumo Life Science Foundation (2015)

21. Kishimoto Foundation (2015)

22. The Tokyo Biomedical Research Foundation (2015)

23. Princess Takamatsu Cancer Research Fund (2015)

24. Okinaka Memorial Institute for Medical Research (2015)

25. Foundation for Promotion of Cancer Research (2015)

26. The Cell Science Research Foundation (2015)

27. the Japan Society for the Promotion of Science (JSPS) Overseas Research Fellowship (April2016 - March 2018)

28. Aplastic Anemia and MDS International Foundation Research Award (2016)

29. Lauri Strauss Leukemia Foundation Research Award (2016)

30. Center of Hematologic Malignancy Annual Retreat Presentation Award (2017)

31. American Society of Hematology (ASH) Abstract Achievement Award (2017)

32. Leukemia and Lymphoma Society Special Fellow Award (2018)

33. American Society of Hematology (ASH) Abstract Achievement Award (2018)

34. AACR Scholar-in-Training Award (2019)



Licence/Certification

1. Medical doctor licence (2003)

2. The Japan Society of Internal Medicine Certifying Physician (2006) 

3. The Japanese Society of Hematology Certifying Hematology Specialist (2011)

4. Occupational Physician (2012)

5. The Japanese Society of Hematology Supervisory Doctor (2013) 

6. The Japanese Society of Internal Medicine Supervisory Doctor (2013)

7. Fellow of the Japanese Society of Internal Medicine (FJSIM) (2014)


Society

1. The Japan Society of Internal Medicine

2. The Japanese Society of Hematology

3. Japanese Cancer Association

4. The Molecular Biology Society of Japan

5. The Japanese Association for Molecular Target Therapy of Cancer

6. The Japan Society for Hematopoietic Cell Transplantation

 

 

 Publication

 

 

1.     Seiler M*, Yoshimi A*, Darman R*, Chan B, Keaney G, Thomas M, Agrawal AA, Caleb B, Csibi A, Sean E, Fekkes P, Karr C, Klimek V, Lai G, Lee L, Kumar P, Lee SC, Liu X, Mackenzie C, Meeske C, Mizui Y, Padron E, Park E, Pazolli E, Peng S, Prajapati S, Taylor J, Teng T, Wang J, Warmuth M, Yao H, Yu L, Zhu P, Abdel-Wahab O, Smith PG, Buonamici S. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nature Medicine 2018 doi: 10.1038/nm.4493. PMID: 29457796

2.     Yoshimi A, Abdel-Wahab O. Targeting mRNA Decapping in AML. Cancer Cell 2018;33(3):339-341. doi: 10.1016/j.ccell.2018.02.015. PMID: 29533777

3.     Miyauchi M, Koya J, Arai S, Yamazaki S, Honda A, Kataoka K, Yoshimi A, Taoka K, Kumano K, Kurokawa M. ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells. Stem Cell Reports 2018;10(3):1115-1130. doi: 10.1016/j.stemcr.2018.01.015. PMID: 29429960

4.     Yoshimi A*, Balasis ME*, Vedder A, Feldman K, Ma Y, Zhang H, Lee SC, Letson C, Niyongere S, Lu SX, Ball M, Taylor J, Zhang Q, Zhao Y, Youssef S, Chung YR, Zhang XJ, Durham BH, Yang W, List AF, Loh ML, Klimek V, Berger MF, Stieglitz E, Padron E, Abdel-Wahab O. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood 2017;130(4):397-407. doi: 10.1182/blood-2017-01-763219. PMID: 28576879

5.     Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin GH, Wang J, Ng V, Xia B, Witkowski MT, Mitchell-Flack M, Grillo I, Bakogianni S, Ndiaye-Lobry D, Martín MT, Guillamot M, Banh RS, Xu M, Figueroa ME, Dickins RA, Abdel-Wahab O, Park CY, Tsirigos A, Neel BG, Aifantis I. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. Cell 2017;170(6):1079-1095.e20. doi: 10.1016/j.cell.2017.07.032. PMID: 28823558

6.     Micol JB, Pastore A, Inoue D, Duployez N, Kim E, Lee SC, Durham BH, Chung YR, Cho H, Zhang XJ, Yoshimi A, Krivtsov A, Koche R, Solary E, Sinha A, Preudhomme C, Abdel-Wahab O. ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nature Communications 2017;8:15429. doi: 10.1038/ncomms15429. PMID: 28516957

7.     Durham BH, Roos-Weil D, Baillou C, Cohen-Aubart F, Yoshimi A, Miyara M, Papo M, Hélias-Rodzewicz Z, Terrones N, Ozkaya N, Dogan A, Rampal R, Urbain F, Le Fèvre L, Diamond EL, Park CY, Papo T, Charlotte F, Gorochov G, Taly V, Bernard OA, Amoura Z, Abdel-Wahab O, Lemoine FM, Haroche J, Emile JF. Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood 2017;130(2):176-180. doi: 10.1182/blood-2016-12-757377. PMID: 28566492

8.     Yoshimi A, Abdel-Wahab O. Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins. Clinical Cancer Research 2017;23(2):336-341. doi: 10.1158/1078-0432.CCR-16-0131. PMID: 27836865

9.     Yoshimi A, Abdel-Wahab O. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T. International Journal of Hematology 2017;105(6):720-731. doi: 10.1007/s12185-017-2242-0. PMID: 28466384

10.  Yoshimi A, Toya T, Nannya Y, Takaoka K, Kirito K, Ito E, Nakajima H, Hayashi Y, Takahashi T, Moriya-Saito A, Suzuki K, Harada H, Komatsu N, Usuki K, Ichikawa M, Kurokawa M. Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan. Annals of Oncology 2016;27(5):887-895. doi: 10.1093/annonc/mdw066. PMID: 26884589

11.  Yoshimi A, Abdel-Wahab O. Defining risk in MDS over time. Blood 2016;128(7):885-886. doi: 10.1182/blood-2016-07-724930. PMID:27539994

12.  Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, Durham BH, Yoshimi A, Kim YJ, Thomas M, Lobry C, Chen CW, Pastore A, Taylor J, Wang X, Krivtsov A, Armstrong SA, Palacino J, Buonamici S, Smith PG, Bradley RK, Abdel-Wahab O. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nature Medicine 2016;22(6):672-678. doi: 10.1038/nm.4097. PMID: 27135740

13.  Masamoto Y, Arai S, Sato T, Yoshimi A, Kubota N, Takamoto I, Iwakura Y, Yoshimura A, Kadowaki T, Kurokawa M. Adiponectin Enhances Antibacterial Activity of Hematopoietic Cells by Suppressing Bone Marrow Inflammation. Immunity. 2016;44(6):1422-1433. doi: 10.1016/j.immuni.2016.05.010. PMID: 27317261

14.  Sakurai M, Kasahara H, Yoshida K, Yoshimi A, Kunimoto H, Watanabe N, Shiraishi Y, Chiba K, Tanaka H, Harada Y, Harada H, Kawakita T, Kurokawa M, Miyano S, Takahashi S, Ogawa S, Okamoto S, Nakajima H. Genetic basis of myeloid transformation in familial platelet disorder/acute myeloid leukemia patients with haploinsufficient RUNX1 allele. Blood Cancer Journal 2016;6:e392. doi: 10.1038/bcj.2015.81. PMID: 26849013

15.  Yamamoto H, Lu J, Oba S, Kawamata T, Yoshimi A, Kurosaki N, Yokoyama K, Matsushita H, Kurokawa M, Tojo A, Ando K, Morishita K, Katagiri K, Kotani A. miR-133 regulates Evi1 expression in AML cells as a potential therapeutic target. Scientific Reports 2016;6:19204. doi: 10.1038/srep19204. PMID: 26754824

16.  Iizuka H, Kagoya Y, Kataoka K, Yoshimi A, Miyauchi M, Taoka K, Kumano K, Yamamoto T, Hotta A, Arai S, Kurokawa M. Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis. Experimental Hematology 2015;43:849-857. doi: 10.1016/j.exphem.2015.05.004. PMID: 2602490

17.  Uni M, Yoshimi A, Yamazaki S, Taoka K, Shinohara A, Nannya Y, Nakamura F, Kurokawa M. Comparison of garenoxacin with levofloxacin as antimicrobial prophylaxis in acute myeloid leukemia. Japanese Journal of Clinical Oncology 2015;45:745-748. doi: 10.1093/jjco/hyv071. PMID: 25989991

18.  Honda A, Yoshimi A, Ushiku T, Shinoda Y, Kawano H, Toya T, Kogure Y, Yamashita H, Kume H, Nannya Y, Kurokawa M. Successful Control of Carcinoma of Unknown Primary with Axitinib, a Novel Molecular-Targeted Agent: A Case Report. Chemotherapy. 2014;60(5-6):342-345. doi: 10.1159/000437135. PMID: 26288144

19.  Kogure Y, Yoshimi A, Ueda K, Nannya Y, Ichikawa M, Nakamura F, Kurokawa M. Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis. Annals of Hematology 2015;94:989-994. doi: 10.1007/s00277-015-2309-z. PMID: 25687839

20.  Yoshimi A*, Toya T*, Kawazu M, Ueno T, Tsukamoto A, Iizuka H, Nakagawa M, Nannya Y, Arai S, Harada H, Usuki K, Hayashi Y, Ito E, Kirito K, Nakajima H, Ichikawa M, Mano H, Kurokawa M. Recurrent CDC25C mutations drive malignant transformation in FPD/AML. Nature Communications 2014;5:4770. doi: 10.1038/ncomms5770. PMID: 25159113

21.  Kagoya Y, Yoshimi A, Kataoka K, Nakagawa M, Kumano K, Arai S, Kobayashi H, Saito T, Iwakura Y, Kurokawa M. NF-kB/TNF-a positive feedback loop with active proteasome machinery supports myeloid leukemia initiating cell capacity. Journal of Clinical Investigation 2014;124:528-542. doi: 10.1172/JCI68101. PMID: 24382349

22.  Kagoya Y, Yoshimi A, Tsuruta-Kishino-T, Arai S, Satoh T, Akira S, Kurokawa M. JAK2V617F-positive myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2. Blood 2014;124:2996-3006. doi: 10.1182/blood-2014-04-570572. PMID: 25217696

23.  Ueda K, Yoshimi A, Kagoya Y, Nishikawa S, Marquez V, Nakagawa M, Kurokawa M. Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of MLL fusion leukemia through up-regulation of p16. Cancer Science 2014;105:512-519. doi: 10.1111/cas.12386. PMID: 24612037

24.  Toya T, Yoshimi A, Morioka T, Arai S, Ichikawa M, Usuki K, Kurokawa M. Development of hairy cell leukemia in familial platelet disorder with predisposition to acute myeloid leukemia. Platelets 2014;25:300-302. doi: 10.3109/09537104.2013.818636. PMID: 23971860

25.  Hangai S, Yoshimi A, Hosoi A, Matsusaka K, Ichikawa M, Fukayama M, and Kurokawa M. An indeterminate result of QuantiFERON-TB Gold In-Tube for miliary tuberculosis due to a high level of IFN-γ production. International Journal of Hematology 2014;99:523-526. doi: 10.1007/s12185-014-1504-3. PMID: 24481938

26.  Sato T, Goyama S, Kataoka K, Nasu R, Tsuruta-Kishino T, Kagoya Y, Nukina A, Kumagai K, Kubota N, Nakagawa M, Arai S, Yoshimi A, Honda H, Kadowaki T, Kurokawa M. Evi1 Defines Leukemia-initiating Capacity and Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia. Oncogene 2014;33:5028-5038. doi: 10.1038/onc.2014.108. PMID: 24747972

27.  Yamazaki S, Nakamura F, Yoshimi A, Ichikawa M, Nannya Y, Kurokawa M. Safety of high-dose micafungin for patients with hematological diseases. Leukemia & Lymphoma 2014;55:2572-2576. doi: 10.3109/10428194.2014.885514. PMID: 24460099

28.  Tanaka M, Suzuki HI, Shibahara J, Kunita A, Isagawa T, Yoshimi A, Kurokawa M, Miyazono K, Aburatani H, Ishikawa S, Fukayama M. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. Oncogene 2014;33:2454-2463. doi: 10.1038/onc.2013.204. PMID: 23752186

29.  Nukina A, Kagoya Y, Watanabe-Okochi N, Arai S, Ueda K, Yoshimi A, Nannya Y, Kurokawa M. Single-cell gene expression analysis reveals clonal architecture of blast-phase chronic myeloid leukaemia. British Journal of Haematology 2014;165:414-416. doi: 10.1111/bjh.12726. PMID: 24401018

30.  Harada S, Yamazaki S, Nakamura F, Morita K, Yoshimi A, Shinozaki-Ushiku A, Fukayama M, Kurokawa M. Autoimmune neutropenia preceding Helicobacter pylori-negative MALT lymphoma with nodal dissemination. International Journal of Clinical and Experimental Pathology 2014;7:6386-6390. PMID: 25337296

31.  Yoshimi A, Kurokawa M. Leukemia Stem Cell and Clonal Evolution. Nihon Rinsho 2014;72(6):1012-1017. PMID: 25016797

32.  Yoshimi A, Kurokawa M. Development of Molecular Targeted Therapy for Hematological Disorder in the Era of Genomic Drug Discovery. Nihon Rinsho 2014;72(6):1005-1011. PMID: 25016797

33.  Watanabe-Okochi N, Yoshimi A, Sato T, Ikeda T, Kumano K, Taoka K, Satoh Y, Shinohara A, Tsuruta T, Masuda A, Yokota H, Yatomi Y, Takahashi K, Kitaura J, Kitamura T, Kurokawa M. The shortest isoform of C/EBPβ, Liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model. Blood 2013;121:4142-4155. doi: 10.1182/blood-2011-07-368654. PMID: 23547050

34.  Uni M,Yoshimi A, Nakamura F, Takazawa Y, Fukayama M, Kurokawa M. Successful allogeneic stem cell transplantation for Lennert lymphoma. Annals of Hematology 2013;92:859-860. doi: 10.1007/s00277-012-1642-8. PMID: 23224245

35.  Ichikawa M, Yoshimi A, Nakagawa M, Nishimoto N, Watanabe-Okochi N, Kurokawa M. A Role for RUNX1 in Hematopoiesis and Myeloid Leukemia. International Journal of Hematology 2013;97:726-734. doi: 10.1007/s12185-013-1347-3. PMID: 23613270

36.  Morita K, Yoshimi A, Masuda A, Ichikawa M, Yatomi H, Kurokawa M. Unique association of Waldenström macroglobulinemia with optic neuritis and monoclonal T-cell expansion. International Journal of Hematology 2013;98:247-249. doi: 10.1007/s12185-013-1372-2. PMID: 23743950

37.  Uni M, Yoshimi A, Maki H, Maeda D, Nakazaki K, Nakamura F, Fukayama M, Kurokawa M. Successful treatment with recombinant thrombomodulin for B-cell lymphoma-associated hemophagocytic syndrome complicated by disseminated intravascular coagulation. International Journal of Clinical and Experimental Pathology 2013;6:1190-1194. PMID: 23696942

38.  Iizuka H, Yoshimi A, Yamamoto G, Masuda A, Nannya Y, Ichikawa M, Yatomi Y, Kurokawa M. Treatment with azacitidine for myelodysplastic syndrome transformed from essential thrombocythemia. Rinsho Ketsueki 2013;54:468-472. PMID: 23727686

39.  Watanabe-Okochi N, Yoshimi A, Sato T, Ikeda T, Kumano K, Taoka K, Satoh Y, Shinohara A, Tsuruta T, Masuda A, Yokota H, Yatomi Y, Takahashi K, Kitaura J, Kitamura T, Kurokawa M. The shortest isoform of C/EBPβ, Liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model. Rinsho Ketsueki 2013;54:749-758. PMID: 24005435

40.  Uni M, Nakamura F, Yoshimi A, Shinozaki-Ushiku A, Hosoi A, Nakazaki K, Nannya Y, Fukayama M, Kurokawa M. Transformation of follicular lymphoma in the retroperitoneal muscles demonstrated by CT-guided needle biopsy of FDG-avid lesions; case series. International Journal of Clinical and Experimental Pathology 2013;7: 402-406. PMID: 24427363

41.  Yoshimi A, Yamamoto G, Goto T, Fukayama M, Kurokawa M. Hepatocellular carcinoma in cirrhotic liver with graft-versus-host disease. Annals of Hematology 2012;91:1501-1502. PMID: 22314841

42.  Miyauchi M, Yoshimi A, Nannya Y, Takazawa Y, Ichikawa M, Fukayama M, Kurokawa M. Efficacy of pleural biopsy for diagnosis of pleural effusion due to chronic GVHD after hematopoietic stem cell transplantation. International Journal of Hematology 2012;96:146-148. doi: 10.1007/s12185-012-1110-1. PMID: 22684925

43.  Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, Arai S, Sato T, Shimabe M, Nakagawa M, Imai Y, Kitamura T, Kurokawa M. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 2011;117:3617-3628. doi: 10.1182/blood-2009-12-261602. PMID: 21289308

44.  Yoshimi A, Kurokawa M. Key Roles of Histone Methyltransferase and Demethylase in Leukemogenesis. Journal of Cellular Biochemistry 2011;112:415-424. doi: 10.1002/jcb.22972. PMID: 21268062

45.  Yoshimi A, Kurokawa M. Evi1 forms a bridge between the epigenetic machinery and signaling pathways. Oncotarget 2011;2:575-586. PMID: 21795762

46.  Arai S, Yoshimi A, Shimabe M, Ichikawa M, Nakagawa M, Imai Y, Goyama S, Kurokawa M. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood 2011;117:6304-6314. doi: 10.1182/blood-2009-07-234310. PMID: 21190993

47.  Kataoka K, Sato T, Yoshimi A, Goyama S, Tsuruta T, Kobayashi H, Shimabe M, Arai S, Nakagawa M, Imai Y, Kumano K, Kumagai K, Kubota N, Kadowaki T, Kurokawa M. Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. Journal of Experimental Medicine 2011;208:2403-2416. doi: 10.1084/jem.20110447. PMID: 22084405

48.  Nakagawa M, Shimabe M, Watanabe-Okochi N, Arai S, Yoshimi A, Shinohara A, Nishimoto N, Kataoka K, Sato T, Kumano K, Nannya Y, Ichikawa M, Imai Y, Kurokawa M. AML1/RUNX1 functions as a cytoplasmic attenuator of NF-{kappa}B signaling in the repression of myeloid tumors. Blood 2011;118:6626-6637. doi: 10.1182/blood-2010-12-326710. PMID: 22021368

49.  Sugaya M, Fujita H, Izutsu K, Oshima K, Takazawa Y, Ohmatsu H, Yoshimi A, Takahashi T, Kanda Y, Kurokawa M, Tamaki K, Sato S. Primary cutaneous anaplastic large cell lymphoma with leg involvement: A case report and review of 11 cases. Journal of Dermatology 2011;38:1009-1012. doi: 10.1111/j.1346-8138.2010.01150.x. PMID: 21434982

50.  Yoshimi A, Nannya Y, Ueda K, Asano D, Yamamoto G, Kumano K, Hangaishi A, Matsui Y, Takahashi T, Imai Y, Sugawara Y, Kokudo N, Kurokawa M. Successful hematopoietic stem cell transplantation from an HLA-identical sibling in a patient with aplastic anemia after HLA-haploidentical living-related liver transplantation for fulminant hepatitis. Biology of Blood and Marrow Transplantation 2009;15:389-390. doi: 10.1016/j.bbmt.2008.11.021. PMID: 19203732

51.  Yoshimi A, Takahashi T, Motokura T, Yatomi Y, Chiba S, Kurokawa M. Hemoperitoneum due to spontaneous rupture of the left gastroepiploic artery in a patient with hemophilia A. Annals of Hematology 2009;88:811-812. doi: 10.1007/s00277-008-0664-8. PMID: 19093114

52.  Shimabe M, Goyama S, Watanabe-Okochi N, Yoshimi A, Ichikawa M, Imai Y, Kurokawa M. Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells. Oncogene 2009;28:4364-4374. doi: 10.1038/onc.2009.288. PMID: 19767769

53.  Yoshimi A, Asai T, Maeda D, Hangaishi A, Sakatani T, Takahashi T, Imai Y, Fukayama M, Kurokawa M. Chronic myelomonocytic leukemia presenting severe uterine hemorrhage due to uterine infiltration of leukemic cells and early-stage endometrial adenocarcinoma. Archives of Gynecology and Obstetrics 2009;280:1077-1078. doi: 10.1007/s00404-009-1086-0. PMID: 19381665

54.  Yoshimi A, Izutsu K, Takahashi M, Kako S, Oshima K, Kanda Y, Motokura T, Chiba S, Momose T, Ohtomo K, Kurokawa M. Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation. American Journal of Hematology 2008;83:477-481. doi: 10.1002/ajh.21158. PMID: 18266206

55.  Yoshimi A, Nannya Y, Sakata-Yanagimoto M, Oshima K, Takahashi T, Kanda Y, Motokura T, Chiba S, Kurokawa M. A myeloablative conditioning regimen for patients with impaired cardiac function undergoing allogeneic stem cell transplantation: Reduced cyclophosphamide combined with etoposide and total body irradiation. American Journal of Hematology 2008;83:635-639. doi: 10.1002/ajh.21208. PMID: 18506704

56.  Yoshimi A, Asai T, Hangaishi A, Takahashi T, Chiba S, and Kurokawa M. Hemorrhagic cystitis in a patient receiving gemtuzumab ozogamicin for relapsed acute promyelocytic leukemia after cord blood transplantation. Annals of Hematology 2008;87:851-852. doi: 10.1007/s00277-008-0482-z. PMID: 18386004

57.  Yoshimi A, Kumano K, Takahashi T, Motokura T, Oota S Chiba S, Fukayama M, Kurokawa M. ESHAP therapy effective in a patient with Langerhans cell sarcoma. International Journal of Hematology 2008;87:532-537. doi: 10.1007/s12185-008-0075-6. PMID: 18415657

58.  Kataoka K, Yamamoto G, Nannya Y, Yoshimi A, Okada S, Asai T, Kumano K, Hangaishi A, Takahashi T, Chiba S, Kurokawa M. Successful engraftment following HLA-mismatched cord blood transplantation for patients with anti-HLA Abs. Bone Marrow Transplantation 2008;42:129-130. doi: 10.1038/bmt.2008.83. PMID: 18362901

59.  Yoshimi A, Taoka K, Nakasone H, Iijima K, Kida M, Iki S, Urabe A, Usuki K. Superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia. Rinsho Ketsueki 2006;47:1533-1538. PMID: 17233472

60.  Yoshimi A, Arai S, Iijima K, Iki S, Usuki K, Urabe A. Effective treatment with rituximab in two patients with Waldenström macroglobulinemia. Rinsho Ketsueki 2005;46:1109-1113. PMID: 16440772

 

 

和文

1.     吉見昭秀
多発性骨髄腫の遺伝子異常とclonal evolution
血液内科 2014,69:461-5

2.     吉見昭秀, 黒川峰夫
ゲノム創薬時代の血液疾患分子標的薬の研究
日本臨牀2014,72:1005-11

3.     吉見昭秀, 黒川峰夫
白血病幹細胞とclonal evolution
日本臨牀2014,72:1012-7

4.     吉見昭秀
AML
の予後を規定する遺伝子発現
血液内科 2014,68:267-72

5.     吉見昭秀
鉄欠乏性貧血の雑学
Medical Practice 2013,30:896

6.     吉見昭秀
難治性AMLの遺伝子発現プロファイル
血液内科 2012,65:665-9

7.     吉見昭秀, 黒川峰夫
難治性AMLにおける遺伝子発現異常
最新医学 2012,67:2466-71

8.     吉見昭秀, 黒川峰夫
正常核型急性骨髄性白血病における遺伝子変異とその意義
Medical Practice 2012,29:1295-8

9.     吉見昭秀
白血病がん遺伝子Evi1を介したエピゲノム異常とシグナル異常
血液内科 2012,64:179-84

10.  吉見昭秀, 黒川峰夫
悪性リンパ腫とエピジェネティクス
CLINICIAN 2011,595:135-40

11.  吉見昭秀, 黒川峰夫
骨髄異形成症候群におけるEZH2変異
血液内科 2011,62:363-8

12.  吉見昭秀, 黒川峰夫
Evi1
遺伝子と白血病
治療学 2010,44:1359-64 

13.  壹岐聖子, 臼杵憲祐, 吉見昭秀, 飯島喜美子, 浦部晶夫
入院日数の短縮と良好なquality of lifeが得られた高齢者再発性急性骨髄性白血病の1
老年者造血器疾患研究会会誌  2008,15:1 9-23

14.  高橋美貴, 藤田英樹, 柴田彩, 多田弥生, 吉見昭秀, 浅井隆司, 菅谷誠, 菊池かな子, 黒川峰夫, 玉置邦彦
MDS
の白血化に伴って生じたcytophasic histiocytic panniculitis1
Skin Cancer 2008,23:234-5


Textbook

1.      吉見昭秀、黒川峰夫
『カラーテキスト血液病学第2版』
2D.骨髄系腫瘍の発症機構 2013; 46-57

2.      吉見昭秀、黒川峰夫
『がん生物学イラストレイテッド』
22.白血病がん遺伝子 2011; 85-93

 

Conference Presentation

1.      13回日本臨床腫瘍学会学術集会
Modified ESHAP regimen for relapsed/refractory T-cell lymphoma: a retrospective analysis.
Yasunori Kogure, Akihide Yoshimi, Koki Ueda, Yasuhito Nannya, Motoshi Ichikawa, Fumihiko Nakamura, Mineo Kurokawa
Department of Hematology & Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Jul 18, 2015, Sapporo、poster

2.      The 6th JSH International Symposium 2015
miR-133 regulates deregulated Evi1 expression in AML cells as a potential therapeutic target without severe adverse effects.
Haruna Yamamoto1), Jen Lu1),2), Shigeyoshi Oba3), Toyotaka Kwamata4), Akihide Yoshimi5), Natsumi Kurosaki1), Kazuaki Yokoyama6), Mineo Kurokawa5), Arinobu Tojo4), Kiyoshi Ando7), Kazuhiro Morishita8), Ai Kotani1)
7),9)
1) Department of Hematological Malignancy, Institute of Medical Science, Tokai University.
2) Department of Intractable Diseases, Institute of National Center for Global Health and Medicine.
3) Department of Nephrology and Endocrinology, the University of Tokyo Hospital.
4) Department of Hematology/ Oncology, Institute of Medical Science, University of Tokyo.
5) Department of Hematology and Oncology, Graduate School of Medicine, the University of Tokyo.
6) Department of Nephrology and Endocrinology, the University of Tokyo Hospital
7) Department of Hematology / Oncology,Tokai University.
8) Department of Medical Science, Faculty of Medicine, University of Miyazaki.
9) Presto/JST
May 22-23, 2015, Karuizawa,

3.      76回日本血液学会学術集会
Modeling chronic myelomonocytic leukemia through patient-derived induced pluripotent stem cells
田岡 和城¹、荒井 俊也²、細井 雅孝²、中村 文彦²、宮内 将²、山崎 翔²、本田 晃²、片岡 圭亮²、熊野 恵城²、吉見 昭秀²、江藤 浩之³、中内 啓光、中畑 龍俊³、黒川 峰夫²
¹東京大学 血液腫瘍内科、²東京大学 血液腫瘍内科/科学技術振興機構、³京都大学iPS細胞研究所、東京大学 医科学研究所
October 31- November 2, 2014,
大阪, Oral presentation

4.      76回日本血液学会学術集会
Adiponectin promotes G-CSF-induced hematopoietic stem and progenitor cell mobilization
正本 庸介¹、荒井 俊也¹、佐藤 智彦¹、吉見 昭秀¹、高本 偉碩²、窪田 直人²、門脇 孝²、黒川 峰夫¹
¹東京大学 血液・腫瘍内科、²東京大学医学部附属病院 糖尿病・代謝内科
October 31- November 2, 2014,
大阪, Oral presentation

5.      76回日本血液学会学術集会
Comparison of garenoxacin with levofloxacin as antimicrobial prophylaxis in acute myeloid leukemia
宇仁 暢大、中村 文彦、山崎 翔、吉見 昭秀、篠原 明仁、黒川 峰夫
東京大学医学部附属病院 血液・腫瘍内科
October 31- November 2, 2014,
大阪, Oral presentation

6.      76回日本血液学会学術集会
Marrow myeloid: Erythroid ratio predicts the latency of erythroid response after azacitidine therapy
山崎 翔、中村 文彦、吉見 昭秀、黒川 峰夫
東京大学 血液・腫瘍内科
October 31- November 2, 2014,
大阪, Poster

7.      73回日本癌学会学術集会
Modeling chronic myelomonocytic leukemia through patient-derived induced pluripotent stem cells
Kazuki Taoka, Shunya Arai, Masataka Hosoi, Fumihiko Nakamura, Masashi Miyauchi, Sho Yamazaki, Akira Honda, Takashi Kobayashi, Keisuke Kataoka, Keiki Kumano, Akihide Yoshimi, Koji Eto, Hiromitsu Nakauchi, Tatsutoshi Nakahara, Mineo Kurokawa
September 25-27, 2014,
横浜, Oral presentation

8.      16th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy
Generation of iPSC from primary CML patient samples
Akihide Yoshimi, Masashi Miyauchi, Tomohiko Sato, Keiki Kumano, Mineo Kurokawa
Department of Hematology & Oncology, Graduate School of Medicine, The University of Tokyo
September 4-7, 2014, Philadelphia, USA, Oral presentation

9.      International Society for Stem Cell Research 12th Annual meeting
Anti-obese hormone adiponectin regulates emergency hematopoiesis and antibacterial response through suppression of TNF
a production in bone marrow and downregulation of SOC3 in hematopoietic stem/progenitor cells
Masamoto, Yosuke1, Arai, Shunya1, Sato, Tomohiko1, Yoshimi, Akihide1, Takamoto, Iseki2, Kubota, Naoto2, Kadowaki, Takashi2, Kurokawa, Mineo1
1University of Tokyo Hospital, Department of Hematology/Oncology, Tokyo, Japan, 2University of Tokyo Hospital, Department of Diabetes and Metabolic Diseases, Tokyo, Japan
June 18-21, 2014, Vancouver, Canada, Poster

10.    東京大学生命科学シンポジウム2014
Recurrent CDC25C mutations drive malignant transformation in FPD/AML
Akihide Yoshimi1, Takashi Toya1, Masahito Kawazu2, Toshihide Ueno3, Ayato Tsukamoto1, Hiromitsu Iizuka1, Masahiro Nakagawa1, Yasuhito Nannya1, Shunya Arai1, Motoshi Ichikawa1, Hironori Harada4, Kensuke Usuki5, Yasuhide Hayashi6, Etsuro Ito7, Keita Kirito8, Hideaki Nakajima9, Hiroyuki Mano3, Mineo Kurokawa1
1Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 2Department of Medical Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 3Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.4Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan. 5Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan. 6Department of Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan. 7Department of Pediatrics, Graduate School of Medicine, Hirosaki University, Aomori, Japan. 8Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan. 9Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
2014
426, 東京, Poster

11.    American Association for Cancer Research 2014
Recurrent CDC25C mutations drive malignant transformation in FPD/AML
Akihide Yoshimi1, Takashi Toya1, Masahito Kawazu2, Toshihide Ueno3, Ayato Tsukamoto1, Hiromitsu Iizuka1, Masahiro Nakagawa1, Yasuhito Nannya1, Shunya Arai1, Motoshi Ichikawa1, Hironori Harada4, Kensuke Usuki5, Yasuhide Hayashi6, Etsuro Ito7, Keita Kirito8, Hideaki Nakajima9, Hiroyuki Mano3, Mineo Kurokawa1
1Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 2Department of Medical Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 3Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 4Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan. 5Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan. 6Department of Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan. 7Department of Pediatrics, Graduate School of Medicine, Hirosaki University, Aomori, Japan. 8Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan. 9Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
April 5-9, 2014, San Diego, USA, Poster

12.    American Association for Cancer Research 2014
Evi1 Defines Leukemia-initiating Capacity and Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia
Tomohiko Sato1,3, Susumu Goyama1, Keisuke Kataoka1, Ryo Nasu1, Takako Tsuruta-Kishino1, Yuki Kagoya1, Arika Nukina1, Katsuyoshi Kumagai2, Naoto Kubota2, Masahiro Nakagawa1, Shunya Arai1, Akihide Yoshimi1, Hiroaki Honda4, Takashi Kadowaki2 and Mineo Kurokawa1
1 Department of Hematology & Oncology, 2 Department of Metabolic and Diabetic Diseases, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan, 3 Department of Transfusion Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan, 4 Department of Disease Model, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan
April 5-9, 2014, San Diego, USA, Poster

13.    55th ASH Annual Meeting and Exposition
The Genetic Landscape Of FPD/AML Revealed CDC25C Mutation As a Driver That Promotes Malignant Transformation
Akihide Yoshimi, MD, PhD1*, Takashi Toya, MD1*, Masahiro Nakagawa, MD, PhD1*, Masahito Kawazu, MD, PhD2*, Yasuhito Nannya, MD, PhD1*, Motoshi Ichikawa, MD, PhD1*, Shunya Arai, MD, PhD1*, Hironori Harada, MD, PhD3, Kensuke Usuki, MD, PhD4*, Yasuhide Hayashi, MD, PhD5*, Etsuro Ito, MD, PhD6, Keita Kirito, MD, PhD7, Hideaki Nakajima, MD, PhD8, Hiroyuki Mano, MD, PhD9 and Mineo Kurokawa, MD, PhD10
1 Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2 Department of Medical Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 3 3Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan, 4 Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan, 5 Department of Hematology/Oncology, Gunma Children's Medical Center, Shibukawa, Japan, 6 Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan, 7 Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan, 8 Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 9 Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 10 Department of Hematology & Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
December 7-10, 2013, New Orleans, USA, Oral presentation

14.    55th ASH Annual Meeting and Exposition
JAK2V617F Mutation Evokes Paracrine DNA Damage To Adjacent Normal Cells Via Secretion Of Lipocalin-2
Yuki Kagoya, MD, PhD1*, Shunya Arai, MD, PhD2*, Akihide Yoshimi, MD, PhD2*, Takako Tsuruta-Kishino1*, Keisuke Kataoka, MD, PhD1* and Mineo Kurokawa, MD, PhD1
1 Department of Hematology & Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2 Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
December 7-10, 2013, New Orleans, USA, Oral presentation

15.    55th ASH Annual Meeting and Exposition
Anti-Obese Hormone Adiponectin Regulates Emergency Hematopoiesis and Antibacterial Response Through Downregulation Of Socs3 In Hematopoietic Progenitor Cells
Yosuke Masamoto, MD, PhD1*, Shunya Arai, MD, PhD1*, Tomohiko Sato, MD, PhD1*, Akihide Yoshimi, MD, PhD1*, Iseki Takamoto, MD, PhD2*, Naoto Kubota, MD, PhD2*, Takashi Kadowaki, MD, PhD2* and Mineo Kurokawa, MD, PhD1
1 Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2 Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
December 7-10, 2013, New Orleans, USA, Oral presentation

16.    55th ASH Annual Meeting and Exposition
A Randomized Controlled Study Evaluating The Efficacy Of Aprepitant For Highly Emetogenic Chemotherapies In Hematological Malignancies
Ryo Nasu, Dr1*, Yasuhito Nannya, MD, PhD2*, Akihide Yoshimi, MD, PhD3*, Masataka Hosoi, M.D., Ph.D.3*, Kouki Ueda, MD, PhD1*, Yumiko Yoshiki, MD, PhD1*, Shunya Arai, MD, PhD3*, Akihito Shinohara, M.D., Ph.D.3*, Fumihiko Nakamura, MD, PhD1* and Mineo Kurokawa, MD, PhD4
1 The University of Tokyo, Tokyo, Japan, 2 Department of Hematology & Oncology,, The University of Tokyo, Tokyo, Japan, 3 Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 4 Department of Hematology & Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
December 7-10, 2013, New Orleans, USA, Poster

17.    36回日本分子生物学会年会
Single-cell gene expression analysis reveals clonal architecture of blast-phase chronic myeloid leukemia
貫名有香,籠谷勇紀,大河内直子,植田航希、吉見昭秀、南谷泰仁、荒井俊也、黒川峰夫
2013.12.3-6,
神戸、Poster

18.    17回日本内分泌病理学会 学術総会
腫瘍退縮時のCT ガイド下針生検結果に苦慮した副腎原発悪性リンパ腫の一例
高士 祐一1),江上 尚子1),髙橋 克敏1),田口  学1),槙田 紀子1),吉見 昭秀2),佐々木弘喜3),佐藤 次郎3),牛久 哲男4),柴原 純二4),福本 誠二1),黒川 峰夫2),深山 正久3),南学 正臣1
1
)東京大学医学部附属病院腎臓・内分泌内科,2)東京大学医学部附属病院血液・腫瘍内科,3)東京大学医学部附属病院放射線科,4)東京大学医学部附属病院病理部
2013
104-5日、横浜、口演

19.    72回日本癌学会総会
Exome sequencing combined with single cell sequencing reveals genetic mechanisms of malignant transformation in FPD/AML
Akihide Yoshimi1, Takashi Toya1, Hiromitsu Iizuka1, Shunya Arai1, Masahiro Nakagawa1, Masahito Kawazu2, Motoshi Ichikawa1, KeitaKirito 3, Hiroyuki Mano4, Mineo Kurokawa1
1 Department of Hematology and Oncology, the University of Tokyo, 2 Department of Medical Genomics, the University of Tokyo, 3 Department of Hematology and Oncology, University of Yamanashi, 4Department of Biochemistry and Molecular Biology, The University of Tokyo
October 3-5, 2013, Yokohama, Japan, Oral presentation

20.    72回日本癌学会総会
JAK2V617F mutation evokes paracrine DNA damage to adjacent cells and drives leukemic transformation
Yuki Kagoya, Akihide Yoshimi, Takako Tsuruta-Kishino, Keisuke Kataoka, Shunya Arai, Mineo Kurokawa
Department of Hematology and Oncology, The University of Tokyo
October 3-5, 2013, Yokohama, Japan, Oral presentation

21.    76回日本血液学会学術集会
Clonal and mutational evolution reveals genetic mechanisms of leukemia transformation of FPD/AML
Akihide Yoshimi:1
Takashi Toya:1Hiromitsu Iizuka:1Shunya Arai:1Masahiro Nakagawa:1Masahito Kawazu:2Motoshi Ichikawa:1Keita Kirito:3Hiroyuki Mano:4Mineo Kurokawa:1
1:Department of Hematology and Oncology, the University of Tokyo
2:Department of Medical Genomics, the University of Tokyo3:Department of Hematology and Oncology, University of Yamanashi4:Department of Biochemistry and Molecular Biology, The University of Tokyo
October 11-13, 2013, Sapporo, Japan, Oral presentation

22.    76回日本血液学会学術集会
JAK2V617F mutation evokes paracrine DNA damage to adjacent cells and drives leukemic transformation
Yuki Kagoya:1
Akihide Yoshimi:1Takako Tsuruta:1Keisuke Kataoka:1Shunya Arai:1Mineo Kurokawa:1
1:Department of Hematology and Oncology, The University of Tokyo, Japan
October 11-13, 2013, Sapporo, Japan, Oral presentation

23.    76回日本血液学会学術集会
Modified ESHAP regimen for relapsed/refractory T-cell lymphoma: A retrospective analysis
Yasunori Kogure:1
Akihide Yoshimi:1Koki Ueda:1Yasuhito Nannya:1Motoshi Ichikawa:1Fumihiko Nakamura:1Mineo Kurokawa:1
1:Department of Hematology & Oncology, The University of Tokyo
October 11-13, 2013, Sapporo, Japan, Oral presentation

24.    76回日本血液学会学術集会
Adiponectin promotes proliferation of hematopoietic cells in vivo
Yosuke Masamoto:1
Shunya Arai:1Tomohiko Sato:1Akihide Yoshimi:1Iseki Takamoto:2Naoto Kubota:2Takashi Kadowaki:2Mineo Kurokawa:1
1:Department of Hematology and Oncology, The University of Tokyo
2:Department of Metabolic Diseases, The University of Tokyo
October 11-13, 2013, Sapporo, Japan, Oral presentation

25.    76回日本血液学会学術集会
Identification of miRNA targeting Evi1
Haruna Yamamoto:1,2
Kazuaki Yokoyama:3Jun Lu:4Shigeyosi Oba:5Toyotaka Kawamata:6Akihide Yoshimi:7Kazuhiro Morishita:8Mineo Kurokawa:7Ai Koutani:1
1:Department of Regenerative medicine, Tokai University, Medicine
2:Dep.Bioscience.,Sch.Sci.,Kitasato Univ.3:Department of Immunology, Tokai University4:Department of Haematology / Oncology, Tokai University5:Department of Nephrology and Endocrinology, the University of Tokyo Hospital6:Department of Haematology / Oncology, University of Tokyo7:Department of Hematology and Oncology, the University of Tokyo8:Division of Tumor and Cellular Biochemistry, University of Miyazaki
October 11-13, 2013, Sapporo, Japan, Poster

26.    Runx Workshop 2013
Pathological analysis of familial platelet disorder with propensity to myeloid malignancy
Akihide Yoshimi1, Hiromitsu Iizuka1, Takashi Toya1, Tomohiko Sato1, Masahito Kawazu2, Keiki Kumano1, Motoshi Ichikawa1, Keita Kirito3, Hiroyuki Mano2,4, Shunya Arai1, Mineo Kurokawa1
1Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 2Department of Medical Genomics, Graduate School of Medicine, The University of Tokyo, 3Department of Hematology and Oncology, University of Yamanashi, 4Division of Functional Genomics, Jichi Medical University
June 16-19, 2013, Wilsede, Germany, Oral presentation

27.    17回日本がん分子標的治療学会学術集会
TNFa
の自己分泌能と高いプロテアソーム活性によるNF-kBの恒常的活性化が骨髄性白血病幹細胞の増殖に重要な役割を担う
籠谷勇紀、吉見 昭秀、黒川 峰夫
東京大学血液・腫瘍内科
2013
612-14 京都, Oral presentation

28.    The 11th Stem Cell Research Symposium
Adiponectin promotes proliferation of hematopoietic cells in vivo
Yosuke Masamoto, Shunya Arai, Tomohiko Sato, Akihide Yoshimi, Iseki Takamoto, Naoto Kubota, Takashi Kadowaki, Mineo Kurokawa
Department of Hematology & Oncology, Graduate School of Medicine, The University of Tokyo, Japan
May 17, 2013, Tokyo, Japan, Oral presentation

29.    The 11th Stem Cell Research Symposium
Constitutive NF-kB activation maintained by autocrine TNF-a signaling and active proteasome system supports leukemia stem cell capacity
Yuki Kagoya, Akihide Yoshimi, Keisuke Kataoka, Masahiro Nakagawa, Kumano Keiki, Shunya Arai, Mineo Kurokawa
Department of Hematology & Oncology, Graduate School of Medicine, The University of Tokyo, Japan
May 17, 2013, Tokyo, Japan, Poster

30.    53回リンパ網内系学会総会
再発難治性T細胞リンパ腫にに対するmodified ESHAP療法の後方視的検討
木暮泰寛、吉見昭秀、植田航希、南谷泰仁、市川幹、中村文彦、黒川峰夫
東京大学大学院医学系研究科 血液・腫瘍内科学
2013
516-18日、京都、Poster

31.    Keystone Symposia Stem Cell Regulation in Homeostasis and Disease (B7)
NF-kB/TNF-a positive feedback loop with active proteasome system controls leukemia stem cell capacity
Yuki Kagoya, Akihide Yoshimi, Keisuke Kataoka, Masahiro Nakagawa, Keiki Kumano, Shunya Arai, Mineo Kurokawa

Department of Hematology & Oncology, Graduate School of Medicine, The University of Tokyo, Japan
February 24-March 1, 2013, Fairmont Banff Springs, Banff, Alberta, Canada, Poster

32.    Keystone Symposia Stem Cell Regulation in Homeostasis and Disease (B7)
EZH2 targeting as a therapeutic strategy against MLL fusion leukemia stem cell
Koki Ueda, Akihide Yoshimi, Masahiro Nakagawa, Satoshi Nishikawa, Keiki Kumano, and Mineo Kurokawa
Department of Hematology & Oncology, Graduate School of Medicine, The University of Tokyo, Japan
February 24-March 1, 2013, Fairmont Banff Springs, Banff, Alberta, Canada, Poster

33.    17回造血器腫瘍研究会
家族性血小板異常症の病態解析
飯塚浩光、吉見昭秀*、間野博行、荒井俊也、黒川峰夫
東京大学大学院医学系研究科 血液・腫瘍内科学, 東京大学大学院医学系研究科  ゲノム医学講座
2013
22日、宮崎、*Oral presentation

34.    54th ASH Annual Meeting and Exposition
NF-κB/TNF-α Positive Feedback Loop with Active Proteasome Machinery Supports Myeloid Leukemia Initiating Cell Capacity
Yuki Kagoya, Akihide Yoshimi, Shunya Arai, Keisuke Kataoka, Masahiro Nakagawa, Keiki Kumano and Mineo Kurokawa
Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
December 8-11, 2012, Georgia World Congress Center, Atlanta, GA, USA, Oral presentation

35.    54th ASH Annual Meeting and Exposition
Inhibition of EZH2 Depletes MLL Fusion Leukemia Stem Cells Through Restoration of p16 Expression
Koki Ueda1, Akihide Yoshimi1,2, Masahiro Nakagawa1, Satoshi Nishikawa1, Victor E Marquez3, Keiki Kumano1 and Mineo Kurokawa1,2
1Hematology and Oncology, The University of Tokyo, Tokyo, Japan, 2Department of Cell Therapy and Transplantation, The University of Tokyo Hospital, Tokyo, Japan, 3Chemical Biology Laboratory Center for Cancer Research, NCI-Frederick, Frederick, MD
December 8-11, 2012, Georgia World Congress Center, Atlanta, GA, USA, Poster

36.    74回日本血液学会総会
NF-kB-TNF-a positive feedback loop is essential for maintenance of myeloid leukemia stem cells
Yuki Kagoya, Akihide Yoshimi, Shunya Arai, Masahiro Nakagawa, Keiki Kumano, Mineo Kurokawa
Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo
Oct 19-21, 2012, Kyoto, Japan, Oral presentation (plenary session)

37.    74回日本血液学会総会
The histone methyltransferase EZH2 plays a crucial role in MLL-related leukemia
Koki Ueda, Akihide Yoshimi, Masahiro Nakagawa, Satoshi Nishikawa, Keiki Kumano, Mineo Kurokawa
Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo
Oct 19-21, 2012, Kyoto, Japan, Oral presentation

38.    74回日本血液学会総会
Identification of microRNAs targeting Evi-1
Jun Lu1, Shigeyoshi Oba2, Akihide Yoshimi3, Kiyoshi Ando4, Kazuhiro Morishita5, Mineo Kurokawa3, Ai Kotani1
1Tokai University Institute of Innovative Science and Technology, 2Department of Nephrology and Endocrinology, the University of Tokyo Hospital, 3Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, 4Department of Hematology and Oncology, Tokai University School of Medicine, 5Division of Tumor and Cellular Biochemistry, Department of Medical Science, Faculty of Medicine, University of Miyazaki
Oct 19-21, 2012, Kyoto, Japan, Oral presentation

39.    71回日本癌学会学術総会
NF-kB-TNF-a positive feedback loop is universally essential for maintenance of myeloid leukemia stem cells
Yuki Kagoya, Akihide Yoshimi, Shunya Arai, Masahiro Nakagawa, Keiki Kumano, Mineo Kurokawa
Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo
Sep 19-21, 2012, Sapporo, Japan, Oral presentation

40.    71回日本癌学会学術総会
The histone methyltransferase EZH2 plays a crucial role in MLL-related leukemia
Koki Ueda, Akihide Yoshimi, Masahiro Nakagawa, Satoshi Nishikawa, Keiki Kumano, Mineo Kurokawa
Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo
Sep 19-21, 2012, Sapporo, Japan, Oral presentation

41.    8回血液学若手研究者勉強会(麒麟塾)
Evi1
はポリコーム複合体との相互作用を介してエピジェネティックにPTEN の発現を抑制し、AKT/mTOR シグナルを活性化する
吉見昭秀、合山進、渡辺-大河内直子、吉識由美子、南谷泰仁、仁田英里子、荒井俊也、佐藤智彦、島辺宗健、中川正宏、今井陽一、北村俊雄、黒川峰夫
東京大学医学部附属病院 血液・腫瘍内科
2012
77日,品川,Oral presentation

42.    167 日本血液学会例会
本態性血小板血症から骨髄異形成症候群に移行し、アザシチジンが有効であった1
飯塚浩光、山本豪、吉見昭秀、南谷泰仁、市川幹、黒川峰夫
東京大学医学部附属病院 血液・腫瘍内科
2012
33, 東京医科歯科大学, Oral presentation

43.    34回日本分子生物学会年会
Evi1 Is a Stem Cell-Specific Regulator of Self-Renewal Capacity In the Definitive Hematopoietic System
Keisuke Kataoka1*, Tomohiko Sato1*, Akihide Yoshimi1*, Susumu Goyama1*, Takako Tsuruta1*, Shunya Arai1*, Yoichi Imai1*, Katsuyoshi Kumagai2*, Naoto Kubota2*, Takashi Kadowaki2* and Mineo Kurokawa3
1
Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 2Department of Metabolic Disease, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 3Hematology/Oncology, University of Tokyo Hospital, Tokyo, Japan
Dec 13-16, 2011, Yokohama, Japan, Oral presentation

44.    73回日本血液学会総会
LIP, a short isoform of C/EBPbeta, collaborates with Evi1 in leukemogenesis (in Japanese)
Naoko Watanabe-Okochi1,3, Takako Tsuruta1, Akihide Yoshimi1, Tomohiko Sato1,3, Koki Takahashi3, Jiro Kitaura2, Toshio Kitamura2, Mineo Kurokawa1
1Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo, 2Division of Stem Cell Signaling, Institute of Medical Science, the University of Tokyo, 3Division of Transfusion Medicine, the University of Tokyo Hospital
Oct 14-16, 2011, Nagoya, Japan, Oral presentation

45.    73回日本血液学会総会
Characteristics and impact on clinical outcome of pericardial effusions in allo-HSCT recipients
Ryo Nasu, Sachiko Seo, Akihide Yoshimi, Yasuhito Nannya, Motoshi Ichikawa, Mineo Kurokawa
Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo
Oct 14-16, 2011, Nagoya, Japan, Oral presentation

46.    11回日本臨床腫瘍学会学術集会
比護貴史、中村文彦、山口聡子、山崎翔、柴原純二、市川幹、吉見昭秀、深山正久、黒川峰夫
B-cell proliferation is infrequent in adult T-cell leukemia/lymphoma
仙台 2011.8.29-31, Poster

47.    7回血液学若手研究者勉強会(麒麟塾)
Evi-1
は造血幹細胞におけるMLL白血病タンパクの転写標的である
荒井俊也、吉見昭秀、島辺宗健、市川幹、中川正宏、今井陽一、合山進、黒川峰夫
東京大学医学部附属病院 血液・腫瘍内科
2011
64日,品川,Oral presentation11回東京大学生命科学シンポジウム
Evi1 expression marks long-term repopulating hematopoietic stem cells
片岡圭亮、佐藤智彦、吉見昭秀、合山進、荒井俊也、今井陽一、熊谷勝義、窪田直人、門脇孝、黒川峰夫
東京 2011.6.4,  Oral presentation

48.    37th Annual Meeting of the European Group for Blood and Marrow Transplantation
Characteristics and impact on clinical outcome of pericardial effusions in allogeneic HSCT recipients
Ryo Nasu, Sachiko Seo, Akihide Yoshimi, Yasuhito Nannya, Motoshi Ichikawa, Mineo Kurokawa
Apr 3-6, 2011, Paris, France,

49.    52th ASH Annual Meeting and Exposition
Evi1 Is a Stem Cell-Specific Regulator of Self-Renewal Capacity In the Definitive Hematopoietic System
Keisuke Kataoka1*, Tomohiko Sato1*, Akihide Yoshimi1*, Susumu Goyama1*, Takako Tsuruta1*, Shunya Arai1*, Yoichi Imai1*, Katsuyoshi Kumagai2*, Naoto Kubota2*, Takashi Kadowaki2* and Mineo Kurokawa3
1
Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 2Department of Metabolic Disease, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 3Hematology/Oncology, University of Tokyo Hospital, Tokyo, Japan
December 4-7, 2010,  International Drive, Orlando, FL, USA, Oral presentation

50.    33回日本分子生物学会年会・第83回日本生化学会大会
Evi1 Induces a Novel Epigenetic Regulation of PTEN/AKT/mTOR Signaling through Interaction with Polycomb Complexes
Akihide Yoshimi1, Naoko Watanabe-Okochi1, Susumu Goyama1, Yasuhito Nannya1, Eriko Nitta1, Shunya Arai1, Tomohiko Sato1, Munetake Shimabe1, Masahiro Nakagawa1, Yoichi Imai1, Toshio Kitamura2, and Mineo Kurokawa1
1
Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo
2
Division of Stem Cell Signaling, Institute of Medical Science, the University of Tokyo
2010
127-10 大阪, Oral & Poster presentation

51.    72回日本血液学会総会
AML1/Evi1 recruits polycomb complexes and epigenetically regulates PTEN/AKT/mTOR signaling (in Japanese)
Akihide Yoshimi1
, Naoko Watanabe-Okochi1, Susumu Goyama1, Yasuhito Nannya1, Eriko Nitta1, Shunya Arai1, Tomohiko Sato1, Munetake Shimabe1, Masahiro Nakagawa1, Yoichi Imai1, Toshio Kitamura2, and Mineo Kurokawa1
1
Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo, 2Division of Stem Cell Signaling, Institute of Medical Science, the University of Tokyo
2010
924 パシフィコ横浜, Oral presentation

52.    72回日本血液学会総会
Evi1 expression marks long-term repopulating hematopoietic stem cells (in Japanese)
Keisuke Kataoka1*, Tomohiko Sato1*, Akihide Yoshimi1*, Susumu Goyama1*, Takako Tsuruta1*, Shunya Arai1*, Yoichi Imai1*, Katsuyoshi Kumagai2*, Naoto Kubota2*, Takashi Kadowaki2* and Mineo Kurokawa3
1
Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 2Department of Metabolic Disease, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
2010
924 パシフィコ横浜, Oral presentation

53.    72回日本血液学会総会
A mouse model of Evi1-related leukemia (in Japanese)
Naoko Okochi-Watanabe1, Takako Tsuruta1, Akihide Yoshimi1, Shunya Arai1, Kousuke Masamoto1, Akihito Shinohara1, Jiro Kitaura2, Toshio Kitamura2, Mineo Kurokawa1
1Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo, 2Division of Stem Cell Signaling, Institute of Medical Science, the University of Tokyo
2010
924 パシフィコ横浜, Oral presentation

54.    72回日本血液学会総会
Polycomb complexes are essential for the maintenance of AML1/ETO-mediated bone marrow transformation (in Japanese)
Anna Sedukhina, Akihide Yoshimi, Masahiro Nakagawa, Yoichi Imai, Mineo Kurokawa
Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo
2010
924 パシフィコ横浜, Oral presentation69回日本癌学会学術総会
AML1/Evi1
融合タンパクはポリコーム複合体と結合しエピジェネティックにPTEN/AKT/mTORシグナルを制御する (in Japanese)
吉見昭秀,今井陽一,竹下昌孝,合山 進,中川正宏,黒川 峰夫
東京大学血液・腫瘍内科
2010922 大阪, Oral presentation

55.    69回日本癌学会学術総会
AML1/ETO exerts its leukemogenic potential through interaction with polycomb complexes (in Japanese)
Anna Sedukhina, Akihide Yoshimi, Masahiro Nakagawa, Yoichi Imai, Mineo Kurokawa
Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo
2010
922 大阪, Oral presentation

56.    69回日本癌学会学術総会
AML1/ETO exerts its leukemogenic potential through interaction with polycomb complexes (in Japanese)
セドキーナ アンナ,吉見昭秀,中川正宏,今井陽一,黒川 峰夫
東京大学血液・腫瘍内科
2010922 大阪, Oral presentation

57.    69回日本癌学会学術総会
A mouse model of Evi1-related leukemia (in Japanese)
Naoko Okochi-Watanabe1, Takako Tsuruta1, Akihide Yoshimi1, Shunya Arai1, Kousuke Masamoto1, Akihito Shinohara1, Jiro Kitaura2, Toshio Kitamura2, Mineo Kurokawa1
1Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo
2
Division of Stem Cell Signaling, Institute of Medical Science, the University of Tokyo
2010
922 大阪, Oral presentation

58.    69回日本癌学会学術総会
Evi1 expression marks long-term repopulating hematopoietic stem cells (in Japanese)
Keisuke Kataoka1*, Tomohiko Sato1*, Akihide Yoshimi1*, Susumu Goyama1*, Takako Tsuruta1*, Shunya Arai1*, Yoichi Imai1*, Katsuyoshi Kumagai2*, Naoto Kubota2*, Takashi Kadowaki2* and Mineo Kurokawa3
1
Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 2Department of Metabolic Disease, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
2010
922 大阪, Oral presentation

59.    Runx Workshop 2010
Polycomb complexes are essential for the leukemogenic potential of AML1/ETO
Akihide Yoshimi
, Anna Sedukhina, Masahiro Nakagawa, Yoichi Imai, and Mineo Kurokawa
Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo
July 11-14, 2010, Hiroshima, Japan, Oral presentation

60.    14回日本がん分子標的治療学会学術集会 
Evi1
高発現白血病に対する分子標的療法の確立 (in Japanese)
吉見 昭秀,中川 正宏,今井 陽一,黒川 峰夫
東京大学血液・腫瘍内科
2010
77 東京, Oral presentation

61.    Keystone symposia  New Paradigms in Cancer Therapeutics (Z1)
EVI1 Induces a Novel Epigenetic Regulation of PTEN/AKT/mTOR Signaling through Interaction with Polycomb Complexes in Leukemia
Akihide Yoshimi1
, Susumu Goyama1, Naoko Watanabe-Okochi1, Yasuhito Nannya1, Eriko Nitta1, Shunya Arai1, Tomohiko Sato1, Munetake Shimabe1, Masahiro Nakagawa1, Yoichi Imai1, Toshio Kitamura2, and Mineo Kurokawa1
1
Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 113-8655, 2Division of Stem Cell Signaling, Institute of Medical Science, University of Tokyo, Tokyo, Japan, 108-8639
March 23 - 28, 2010,
Victoria Canada, Oral presentation

62.    71回日本血液学会総会
EVI1 Represses PTEN Transcription and Activates AKT/mTOR Through Interaction with Polycomb Repressor complexes
Akihide Yoshimi1
, Naoko Watanabe-Okochi1, Susumu Goyama1, Yasuhito Nannya1, Eriko Nitta1, Shunya Arai1, Tomohiko Sato1, Munetake Shimabe1, Masahiro Nakagawa1, Yoichi Imai1, Toshio Kitamura2, and Mineo Kurokawa1 (in Japanese)
1
Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo, 2Division of Stem Cell Signaling, Institute of Medical Science, the University of Tokyo
2009
1024 国立京都国際会館, Oral presentation (Plenary session)

63.    68回日本癌学会学術総会
EVI1
はポリコーム群を介してPTENの転写を抑制しAKT/mTORシグナルを活性化する (in Japanese)
吉見昭秀1,渡辺-大河内 直子1,合山 1,南谷 泰仁1,仁田 英里子1,荒井 俊也1,佐藤 智彦1,島辺 宗健1,中川 正宏1,今井 陽一1,北村 俊雄2,黒川 峰夫1
1
東京大学血液・腫瘍内科, 2 東京大学医科学研究所幹細胞シグナル制御
2009
103 パシフィコ横浜, Oral presentation

64.    70回日本血液学会総会
心機能低下症例に対する同種造血幹細胞移植における新たな骨髄破壊的前処置 (in Japanese)
1
吉見昭秀1南谷泰仁,1柳元麻実子,1大島久美,1神田善伸,1高橋強志,1本倉徹,2千葉滋,1,2黒川峰夫
1
東京大学 血液・腫瘍内科, 2東京大学医学部附属病院 無菌治療部
2008
1012 国立京都国際会館, Poster

65.    555回日本内科学会関東地方会
子宮浸潤を伴った慢性骨髄単球性白血病の1 (in Japanese)
東京大学血液・腫瘍内科
那須 涼,片岡 圭亮,市川 幹,吉見昭秀,浅井 隆司,半下石 明,高橋 強志,今井 陽一,黒川峰夫
2008
713 日本都市センター, Oral presentation

66.    48回日本リンパ網内系学会総会
Allo-PBSCT
を行った primary cutaneous anaplastic large cell lymphoma の一例 (in Japanese)
菅谷誠, 藤田英樹, 伊豆津宏二, 大島久美, 高澤豊, 大松華子, 吉見昭秀, 高橋強志, 神田善伸, 深山正久, 千葉滋, 黒川峰夫, 玉置邦彦
2008
613 札幌, Poster

67.    105 日本内科学会総会・講演会
心機能低下患者に対する新たな骨髄破壊的前処置を用いた同種造血幹細胞移植の検討 (in Japanese)
東京大学医学部附属病院 血液・腫瘍内科
吉見昭秀, 南谷 泰仁, 大島 久美, 柳元 麻実子, 高橋 強志, 神田 善伸, 本倉 , 千葉 , 黒川 峰夫
2008
411 東京国際フォーラム,Poster

68.    6 日本臨床腫瘍学会学術集会
悪性リンパ腫患者におけるFDG-PET所見と同種造血幹細胞移植の成績の検討 (in Japanese)
東京大学医学部附属病院 血液・腫瘍内科
吉見昭秀, 伊豆津宏二,大島 久美南谷 泰仁高橋 強志, 神田 善伸, 本倉 , 千葉 , 黒川 峰夫
2008
320 福岡国際会議場, Poster

69.    552 日本内科学会関東地方会
劇症肝炎に対する自己肝温存生体肝移植後に再生不良性貧血を発症し、2回のATG投与を施行した症例 (in Japanese)
白井 裕生、植田 航希、吉見昭秀、山本 豪、南谷 泰仁、半下石 明、高橋 強志、千葉 滋、黒川 峰夫
2008
38 日内会館, Oral presentation

70.    30 日本造血細胞移植学会総会
悪性リンパ腫患者におけるFDG-PETと同種造血幹細胞移植の成績の検討 (in Japanese)
東京大学医学部附属病院 血液・腫瘍内科
吉見昭秀, 伊豆津宏二,大島 久美南谷 泰仁高橋 強志, 神田 善伸, 本倉 , 千葉 , 黒川 峰夫
2008
229 大阪国際会議場, Poster

71.    30 日本造血細胞移植学会総会
心機能低下症例の造血幹細胞移植に対する減量エンドキサンとラステット,全身放射線照射を用いた骨髄破壊的前処置 (in Japanese)
東京大学医学部附属病院 血液・腫瘍内科
南谷 泰仁,吉見昭秀, 柳元麻実子, 高橋 強志, 半下石 , 本倉 ,黒川 峰夫
東京大学無菌治療部     千葉
2008
229 大阪国際会議場,Poster

72.    49th ASH Annual Meeting and Exposition
Reduced Cyclophosphamide Combined with Etoposide and Total Body Irradiation as a Conditioning Regimen for Patients with Impaired
Cardiac Function Undergoing Allogeneic Stem Cell Transplantation
Akihide Yoshimi
, Yasuhito Nannya, Kumi Oshima, Mamiko Sakata-Yanagimoto, Tsuyoshi Takahashi, Yoshinobu Kanda, Toru Motokura,
Shigeru Chiba, and Mineo Kurokawa
Department  of  Hematology  and  Oncology,  Graduate  School  of  Medicine, University of Tokyo, Tokyo, Japan
December 8-11, 2007, Georgia World Congress Center, Atlanta, Georgia, USA, Poster

73.    549回日本内科学会関東地方会
生体肝移植後に発症しESHAP療法が奏効したLangerhans cell sarcoma (in Japanese)
東京大学血液・腫瘍内科
吉見昭秀, 熊野恵城, 高橋強志, 本倉 徹, 千葉 滋, 黒川峰夫
同 病理部  高澤 豊, 太田 聡, 深山正久
2007
1110 日内会館, Oral presentation

74.    69回日本血液学会・第49回日本臨床血液学会(合同総会)
同種造血幹細胞移植の予後予測におけるFDG-PETの意義 (in Japanese)
吉見昭秀、伊豆津宏二、大島久美、南谷泰仁、高橋強志、神田善伸、本倉徹、千葉滋、黒川峰夫
東京大学血液・腫瘍内科
2007
1013 パシフィコ横浜, Oral presentation

75.    546回日本内科学会関東地方会例会
左胃大網動脈から自然出血を来たし動脈塞栓術が有効であった血友病A1 (in Japanese)
東京大学血液・腫瘍内科
吉見昭秀, 高橋強志, 神田善伸, 本倉 徹, 千葉 滋, 黒川峰夫
東京大学医学部附属病院検査部
金子 誠, 矢冨 裕
2007
722 日本都市センター, Oral presentation

76.    541回内科学会関東地方会
急性発症した特発性血小板減少性紫斑病(ITP)のため,内視鏡的大腸ポリープ切除後に出血を来した1 (in Japanese)
東京大学消化器内科 小林由佳,八島陽子,山路裕,小椋啓司,岡本真,川邊隆夫,小俣政男
血液腫瘍内科 吉見昭秀,半下石明,黒川峰夫
2006
1210, Oral presentation

77.    156回日本臨床血液学会例会
寛解導入療法中に上矢状静脈洞血栓症を来たした急性リンパ性白血病 (in Japanese)
吉見昭秀,田岡和城,仲宗根秀樹,飯島喜美子、木田理子,壹岐聖子,浦部晶夫,臼杵憲祐
NTT
関東病院血液内科
2006
7月1日 名古屋国際会議場, Oral presentation

78.    103回日本内科学会講演会
発熱外来患者の原因疾患 (in Japanese)
渋谷祐子, 奈美, 鈴木快文, 広池 紀奈, 中田泰之, 熊谷真義, 吉見昭秀, 五味朋子
NTT
東日本関東病院腎臓内科・内科
2006
414日~16日、Poster

79.    155回日本臨床血液学会例会
AML
発症時にベーチェット病の症状を認めた一例 (in Japanese)
玉島順子, 壹岐聖子, 吉見昭秀, 飯島喜美子, 臼杵憲祐, 浦部晶夫                     
NTT
関東逓信病院 血液内科
2006
2 東京, Oral presentation

80.    154回日本臨床血液学会例会
パルボウィルスB19PVB19)感染によりaplastic crisisを呈した2 (in Japanese)
飯島喜美子、吉見昭秀、壹岐聖子、臼杵憲祐、浦部晶夫
NTT
関東病院血液内科 
2005
1119 東京医科歯科大学, Oral presentation

81.    153回日本臨床血液学会例会
皮膚病変に対しタクロリムスが奏効した血管免疫芽球性T細胞リンパ腫 (in Japanese)
荒井俊也、吉見昭秀、飯島喜美子、壹岐聖子、臼杵憲祐、浦部晶夫
NTT
関東病院血液内科
2005
618 慶應義塾大学, Oral presentation

82.    152回日本臨床血液学会例会
Rituximab
が奏効した原発性マクログロブリン血症の2 (in Japanese)
吉見昭秀、荒井俊也、飯島喜美子、壹岐聖子、臼杵憲祐、浦部晶夫
NTT
関東病院血液内科
2005
226 順天堂大学, Oral presentation

83.    152回日本臨床血液学会例会
非ホジキンリンパ腫、腎細胞癌、大腸癌の3重癌症例 (in Japanese)
荒井俊也、吉見昭秀、飯島喜美子、壹岐聖子、臼杵憲祐、浦部晶夫
NTT
関東病院血液内科
2005
226 順天堂大学, Oral presentation

Subpages (1): CV